Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levofolinic acid - Acrotech Biopharma

Next Previous
Drug Profile

Levofolinic acid - Acrotech Biopharma

Alternative Names: Calcium levofolinate; Calcium levoleucovorin; FUSILEV; Isovorin; KHAPZORY; Levofolinate; Levofolinate calcium; Levoleucovorin; Levoleucovorin calcium pentahydrate

Latest Information Update: 21 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth
  • Developer Acrotech Biopharma
  • Class Antidotes; Antineoplastics; Formyltetrahydrofolates; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Colorectal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaemia; Colorectal cancer; Osteosarcoma

Most Recent Events

  • 17 Jan 2025 Merck Sharp & Dohme plans a phase I/II Substudy 06E trial for Oesophageal cancer (Combination therapy, Late-stage disease, Metastatic disease) in January 2025 (NCT06780111)
  • 06 Mar 2019 Spectrum Pharmaceuticals completes sale of levofolinic acid to Acrotech Biopharma
  • 17 Jan 2019 Spectrum Pharmaceuticals and Acrotech Biopharma enters into a definitive agreement to sell Levofolinic acid

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top